Allogene appoints Stephen Mayo, Ph.D. to Board; board expands to 12

Allogene Therapeutics, Inc.

Board increased from 11 to 12; Mayo appointed as Class III director, term expires at 2024 annual meeting.
Annual cash retainer of $40,000 for board service under non-employee director compensation policy.
Initial equity grants: option and RSU each with $425,000 grant date value, vesting over 3 years and 3 annual installments.
Director eligible for annual automatic option/RSU grants with $425,000 value on each annual meeting date.
Equity grants accelerate fully upon change in control.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stephen Mayo

Director

ALLO · Allogene Therapeutics, Inc.

Effective: 2022-07-08
Filed: July 12, 2022, 7:59 PM ET

On July 8, 2022, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the authorized number of directors on the Board from eleven to twelve, and appointed Stephen Mayo, Ph.D. as a Class III director of the Company to fill the newly created vacancy, effective immediately, with a term of office expiring at the Company’s 2024 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Mayo was appointed as Director at Allogene Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 8, 2022, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the authorized number of directors on the Board from eleven to twelve, and appointed Stephen Mayo, Ph.D. as a Class III director of the Company to fill the newly created vacancy, effective immediately, with a term of office expiring at the Company’s 2024 annual meeting of stockholders.

View on SEC.gov

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-22-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.